. 2022 Feb 24;9:803692. doi: 10.3389/fmed.2022.803692

Table 1.

Patients with chronic actinic dermatitis (CAD) treated with dupilumab (n = 3).

	Patient 1	Patient 2	Patient 3
Age	58	77	69
Sex	Male	Male	Male
Duration of CAD (Years)	>10	4	1
Clinical presentation	Well-demarcated Erythematous excoriated lichenified pruritic plaques on sun-exposed areas (face, fore arm, dorsa of hands and scalp), increased symptoms in summer during outdoor activities. Spared shaded areas.	Pruritic edematous excoriated lichenified plaques on sun-exposed areas (face, upper chest, dorsa of hands and scalp), increased symptoms in summer specially during outdoor activities. Shaded areas are spared.	Well-demarcated phot-induced eczematous on sun-exposed areas (face, upper chest, fore arm, dorsa of hands and scalp), increased symptoms in summer during outdoor activities. No lesion were found on the shaded areas of the body.
Serum IgE levels	150 IU/mL (normal 20–200 IU/mL)	88 IU/mL (normal 20–200 IU/mL)	Not done
Severity measurement tools (IGA, EASI, Pruritic-NRS)	IGA: 4^v0/1^A EASI: 10.3^v0/1^A BSA:21^v0/6^A Pruritic-NRS: 7^v0/2^A	IGA: 4^v0/1^A EASI: 13^v0/1.7^A BSA:20^v0/8^A Pruritic-NRS: 8^v0/1^A	IGA: 4^v0/2^A EASI: 11^v0/2^A BSA:26^v0/10^A Pruritic-NRS: 8^v0/3^A
Previous treatment	Corticosteroid (T, PO), TCI, methotrexate, antihistamine, hydroxychloroquine (2)	Corticosteroid (T, PO), TCI, methotrexate, Azathioprine, hydroxychloroquine, mycophenolate mofetil (2)	Corticosteroids (T), TCI, antihistamines and hydroxychloroquine (2)
Photo-testing (MED)	UVA: positive at 7 mJ/cm2 at 24 h (normal range: ≥10 mJ/cm2 ) UVB: positive at 25 mJ/cm2 at 24 h (normal range: ≥40 mJ/cm2 )	UVA: negative at 24 h UVB: positive at 15 mJ/cm2 at 24 h (normal range: ≥40 mJ/cm2)	UVA: positive at 3 mJ/cm2 at 24 h (normal range: ≥10 mJ/cm2 ) UVB: positive at 18 mJ/cm2 at 24 h (normal range: ≥40 mJ/cm2 )
Treatment with Dupilumab	Dupilumab 600 mg, 300 mg biweekly+ hydroxychloroquine	Dupilumab 600 mg, 300 mg biweekly+ hydroxychloroquine	Dupilumab 600 mg, 300 mg biweekly+ hydroxychloroquine
Treatment duration	16 weeks (continued)	20 weeks (continued)	8 weeks (continued)
Follow up	Clearance of lesions	Nearly clearance of lesions.	Significant reduced pruritus and rash
Overall effects	↑↑↑	↑↑↑	↑↑
Complications	none	none	none
Comments	History of AD Yes	no	no

PO, per oral; T, topical; TCIs, topical calcineurin inhibitors; MED, minimal erythema dose; V0, visit zero; A, after treatment; overall effects: → , none; ↑, mild; ↑↑, moderate; ↑↑↑, complete.